AIMD - Ainos, Inc. Stock Price, Fair Value and News

0.67USD-0.02 (-2.90%)Market Closed

Market Summary

USD0.67-0.02

Market Closed

-2.90%

AIMD Stock Price

View Fullscreen

AIMD RSI Chart

AIMD Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

44.95

EV/EBITDA

-0.33

Price/Free Cashflow

-0.93

AIMD Price/Sales (Trailing)

AIMD Profitability

Operating Margin

-222.12%

EBT Margin

-15547.13%

Return on Equity

-64.22%

Return on Assets

-48.95%

Free Cashflow Yield

-107.19%

AIMD Fundamentals

AIMD Revenue

Revenue (TTM)

93.7K

Rev. Growth (Yr)

-96.11%

Rev. Growth (Qtr)

4.14%

AIMD Earnings

Earnings (TTM)

-14.6M

Earnings Growth (Yr)

-31.52%

Earnings Growth (Qtr)

44.05%

Breaking Down AIMD Revenue

Last 7 days

-10.7%

Last 30 days

-21.2%

Last 90 days

-35.6%

How does AIMD drawdown profile look like?

AIMD Financial Health

Current Ratio

0.32

AIMD Investor Care

Buy Backs (1Y)

68.64%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.7K	0	0	0
2023	2.7M	1.8M	971.5K	122.1K
2022	679.6K	1.1M	2.5M	3.5M
2021	161.1K	305.6K	450.1K	594.6K
2020	22.9K	22.7K	18.1K	16.6K
2019	25.2K	25.6K	15.4K	11.7K
2018	307.5K	57.3K	72.2K	77.7K
2017	0	195.9K	223.4K	250.9K
2016	113.4K	140.9K	168.4K	0
2015	0	0	0	85.9K
2011	18.5K	31.8K	45.1K	58.4K
2010	0	0	0	5.2K

Get all data in R, Python etc through our Historical Stock Data APIs

About Ainos, Inc.

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

CEO	Mr. Chun-Hsien Tsai
WEBSITE	ainos.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	43

Ainos, Inc. Frequently Asked Questions

What is the ticker symbol for Ainos, Inc.? What does AIMD stand for in stocks?

AIMD is the stock ticker symbol of Ainos, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ainos, Inc. (AIMD)?

As of Fri Jul 26 2024, market cap of Ainos, Inc. is 4.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIMD stock?

You can check AIMD's fair value in chart for subscribers.

Is Ainos, Inc. a good stock to buy?

The fair value guage provides a quick view whether AIMD is over valued or under valued. Whether Ainos, Inc. is cheap or expensive depends on the assumptions which impact Ainos, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIMD.

What is Ainos, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AIMD's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 44.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIMD PE ratio will change depending on the future growth rate expectations of investors.